Compare
Zura Bio Ltd vs Lineage Cell Therapeutics, Inc. vs Humacyte, Inc. vs Kalaris Therapeutics, Inc.
| Latest fiscal year | Zura Bio Ltd ZURA | Lineage Cell Therapeutics, Inc. LCTX | Humacyte, Inc. HUMA | Kalaris Therapeutics, Inc. KLRS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $14.56M | $2.04M | n/a |
| Revenue growth (YoY) | n/a | +53.2% | n/a | n/a |
| Gross margin | n/a | n/a | -376.1% (computed) | n/a |
| Operating margin | n/a | -251.6% | n/m | n/a |
| Net margin | n/a | -436.5% | n/m | n/a |
| Net income | -$68.65M | -$63.53M | -$40.83M | -$43.44M |
| EPS (Diluted) | -$1.06 | -$0.28 | -$0.26 | -$2.85 |
| Operating cash flow | -$64.81M | -$18.92M | -$105.04M | -$38.37M |
| Free cash flow | -$64.93M | -$19.44M | -$105.93M | -$38.57M |
| Cash & equivalents | $109.41M | $40.79M | $50.50M | $98.05M |
| Total assets | $113.95M | $112.58M | $116.37M | $121.74M |
| Total liabilities | $12.41M | $69.24M | $113.26M | $42.92M |
| Shareholders' equity | $101.54M | $43.35M | $3.11M | $78.81M |
| Return on year-end equity | -67.6% | -146.6% | n/m | -55.1% |
| Shares outstanding | 73.68M | 243.12M | 193.00M | 22.90M |
Revenue, most recent five fiscal years
| Fiscal year | Zura Bio Ltd | Lineage Cell Therapeutics, Inc. | Humacyte, Inc. | Kalaris Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $14.56M Ended 2025-12-31 | $2.04M Ended 2025-12-31 | $165.0K Ended 2019-12-31 |
| 1 year earlier | n/a | $9.50M Ended 2024-12-31 | $0 Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $8.95M Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | $14.70M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $4.34M Ended 2021-12-31 | n/a | n/a |